Avicanna Secures US Patent for Cannabinoid-Based Topical Formulation Targeting Skin Conditions
Key Insights
Avicanna Inc. (search) received US Patent No. 12,343,315 B2 from the USPTO covering topical cannabinoid gel formulations for treating skin diseases including acne (search), wrinkles, rosacea (search), and erythema (search).
The patented formulation combines cannabinoids with antioxidants, anti-microbial agents, and anti-inflammatory agents in a topical gel delivery system.
The patent covers compositions already integrated into Avicanna's commercial platforms and pharmaceutical pipeline, expanding the company's intellectual property portfolio.
The U.S. Patent and Trademark Office has issued Patent No. US 12,343,315 B2 to Avicanna Inc. (search), covering the company's topical cannabinoid gel formulations designed to treat various skin conditions. The patent represents a significant addition to Avicanna's intellectual property portfolio as the commercial-stage biopharmaceutical company continues advancing cannabinoid-based therapeutics.
Patent Specifications and Therapeutic Applications
The issued patent covers a topical gel formulation that combines cannabinoids with antioxidants, anti-microbial agents, and anti-inflammatory agents. According to the patent documentation, the formulation targets multiple dermatological conditions including acne (search), wrinkles, rosacea (search), and erythema (search), positioning it for both therapeutic and cosmetic applications.
"We are delighted with the issuance of another USPTO patent as we continue to expand our intellectual property portfolio," stated Aras Azadian, CEO of Avicanna. "We are excited about the potential of this patent that covers our composition that are in our commercial platforms and pharmaceutical pipeline."
Commercial Integration and Development Pipeline
The patented compositions are already incorporated into Avicanna's existing commercial platforms and pharmaceutical development pipeline. This integration suggests the company has moved beyond research phases into practical application and potential market deployment of the protected formulations.
Avicanna's pharmaceutical pipeline leverages the company's scientific platform, vertical integration, and real-world evidence to develop proprietary, indication-specific cannabinoid-based candidates. These candidates are currently in various stages of clinical development and specifically target unmet medical needs in dermatology, chronic pain (search), and neurological disorders (search).
Business Platform Structure
Avicanna operates through four commercial-stage business pillars that support its cannabinoid-based product development and commercialization strategy. The medical cannabis formulary, branded as RHO Phyto™, offers proprietary products across multiple delivery methods including oral, sublingual, topical, and transdermal formulations with varying cannabinoid ratios. This established brand maintains nationwide availability across Canada and is expanding into international markets.
The company's medical cannabis care platform, MyMedi.ca, operates through Northern Green Canada Inc. (search) and provides pharmacist-led patient support programs, specialty services for veterans, and collaboration with public and private payers for reimbursement services. The platform also delivers educational resources to the medical community to facilitate medical cannabis integration into healthcare regimens.
Supply Chain and Manufacturing Capabilities
Avicanna's active pharmaceutical ingredients division operates through its majority-owned subsidiary Santa Marta Golden Hemp SAS (search) (SMGH), which supplies high-quality CBD, THC, and CBG (search) to international partners for food, cosmetics, medical, and pharmaceutical product development. SMGH serves as both a commercial-stage business and an integral component of Avicanna's supply chain, providing reliable input products for the company's consumer retail, medical cannabis, and pharmaceutical products globally.